{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-25-000006","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.211872+00:00","generated_at":"2026-05-28T03:24:21.315258+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Caribou Biosciences initiates lupus trial, plans 2025 data milestones, hires new CFO","bullets":["Initiated GALLOP Phase 1 trial of CB-010 in lupus nephritis and extrarenal lupus; FDA Fast Track for refractory SLE.","CB-010 ANTLER and CB-011 CaMMouflage Phase 1 data expected H1 2025; CB-010 pivotal Phase 3 planned H2 2025 pending HLA matching.","CB-012 AMpLify Phase 1 in r/r AML: dose level 3 completed with no DLTs; enrolling dose level 4.","Sri Ryali appointed CFO; $281M cash expected to fund operations into H2 2026.","CB-012 granted FDA Fast Track and Orphan Drug designation for r/r AML."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-25-000006","json":"https://secwatch.observer/filing/0001619856-25-000006.json","markdown":"https://secwatch.observer/filing/0001619856-25-000006.md","text":"https://secwatch.observer/filing/0001619856-25-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985625000006/0001619856-25-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985625000006/crbu-20250112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:24:21.315258+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}